%0 Generic
%A Piccart, M.
%A Ruiz Borrego, M.
%A Duhoux, F.
%A Arkenau, H-T.
%A Doger de Speville, B.
%A Wildiers, H.
%A Campone, M.
%A Tosi, D.
%A Garcia-Corbacho, J.
%A Jimenez, B.
%A Escriva-de Romani, S.
%A Wardley, A. M.
%A Tassone, P.
%A Boni, V.
%A Jerez, Y.
%A Aftimos, P. G.
%A Hennequin, A.
%A Amair-Pinedo, F.
%A Pellacani, A. U. E.
%A Laurent, D. O.
%T Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)
%D 2020
%@ 0923-7534
%U https://hdl.handle.net/10668/27097
%~